Drug Search Results
More Filters [+]

PF-00592379

Alternative Names: pf-00592379, pf00592379, pf 00592379
Latest Update: 2006-08-24
Latest Update Note: Clinical Trial Update

Product Description

For restoring penile erections in patients with erectile dysfunction

Mechanisms of Action: CRFR Antagonist

Novel Mechanism: Yes

Modality: N/A

Route of Administration: N/A

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: Pfizer
Company Location: NEW YORK NY 10017
Company CEO: Albert Bourla
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for PF-00592379

Countries in Clinic:

Active Clinical Trial Count:

Highest Development Phases

Phase 2: Erectile Dysfunction

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

2005-004648-30

P2

Completed

Erectile Dysfunction

2006-06-29

A7771002

P2

Completed

Erectile Dysfunction

None

Recent News Events

Date

Type

Title